We recently published 10 Big Names Bleed Double Digits. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the ...

September S&P 500 E-Mini futures (ESU25) are trending up +0.24% this morning as investors digested U.S. President Donald ...

Vertex Pharmaceuticals stock sold off on two pipeline disappointments. The biotech company continues to grow with promising ...

Major indexes fell Tuesday as stocks gave back a chunk of the previous session's gains amid ongoing concerns about tariffs and the economic outlook.

Vertex Pharmaceuticals Inc.’s bad news from a phase II pain study and separately on the regulatory front caused shares ...

Key Takeaways The S&P 500 declined 0.5% on Tuesday, Aug. 5, 2025, as a key gauge of the services sector showed a slump in July and trade talks remained in focus.Gartner shares tumbled after the IT ...

The Dow Jones Industrial Average ended the day 0.1% lower, or around 62 points. The 30-stock index closed below its 21-day ...

What Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the ...

Key Takeaways U.S. equities declined at midday following a soft services industry report and President Donald Trump's ...

Vertex Pharmaceuticals (VRTX) posts strong Q2 earnings and revenue growth but faces a 17% stock drop after mid-stage pain drug failure. Read more here.

CRISPR Therapeutics (CRSP) stock falls as company's Q2 results miss consensus amid focus on its Cagevy gene therapy developed with Vertex Pharma (VRTX). Read more here.